Desiree Beutelspacher is the Vice President of Operations at Retinagenix. She brings with her over 20 years of drug development experience. Seventeen of those years have been spent in the early development of ophthalmic compounds, with an emphasis on retinal diseases such as wet and dry age-related macular degeneration. Desiree was previously Vice President of Clinical Operations at Kodiak Sciences working on an extended duration anti-VEGF agent. Prior to Kodiak, she worked at Ophthotech Corporation, where she led the clinical operations for the Fovista™ franchise, Phase 1 through Phase 3. Desiree has also worked as an independent clinical consultant collaborating with small biotech companies to develop early-stage clinical programs. She holds a B.S. in biology from UCLA and has a PMP certification.